Eli Lilly's would-be rival to Pfizer's Ibrance (palbociclib) just gained an inside track at the FDA. Regulators handed Lilly the coveted "breakthrough therapy" designation for abemaciclib, another CDK 4/6 inhibitor with big plans for carving out a niche among patients with advanced breast cancer.
Recently, Eli Lilly and Boehringer Ingelheim's Jardiance became the first diabetes drug to show it could reduce the combined risk of heart attack, stroke and death from cardiovascular causes--doing so by 14% in a study of high-risk Type 2 diabetes patients. But payers aren't exactly running to redo their formularies.
Fremont, CA-based Zosano delivered bitter news to its investors on Monday evening, tipping off the market that Eli Lilly had bowed out of their osteoporosis partnership while it had also decided to halt work on a daily dosing program. The news, delivered during a bearish period for biotech stocks, eviscerated its stock, which dropped 43% and reduced its market cap to a mere $42 million.
Eli Lilly and Incyte are now three for three Phase III studies for baricitinib, an oral JAK inhibitor for rheumatoid arthritis that is on track for a marketing application and a real-world test of its lofty blockbuster reputation with analysts--while one already established rival from Pfizer lags well behind expectations.
Top-line data on Eli Lilly and Boehringer Ingelheim's SGLT2 med, Jardiance, is out, showing the drug cut the combined risk of heart attack, stroke and death from cardiovascular causes by 14% in high-risk Type 2 diabetes patients. But what does it mean for the ultracompetitive diabetes landscape?
Since Eli Lilly and Boehringer Ingelheim announced that their SGLT2 med, Jardiance, had become the first to show it could lower the risk of major cardiovascular events, the question on the minds of industry watchers has been "How much?"
Late last month, Eli Lilly and Boehringer Ingelheim said their SGLT2 med, Jardiance, became the first diabetes med to show it could actually lower the risk of heart attack, stroke and death from cardiovascular causes. But even with that potentially hefty benefit, payers aren't getting ahead of themselves.
Eli Lilly has high hopes for its new oncology med Cyramza, notching U.S. approvals for the drug last year to counter slumping sales and increased competition to older products. But the company could face a setback with Cyramza across the pond, as the U.K.'s cost gatekeeper is holding off on recommending the drug to treat certain forms of stomach cancer.
Eli Lilly, blueprinting an R&D hub outside Boston, is expanding the square footage of its new outpost, snatching up more of the increasingly costly lab space in biotech's most in-demand neighborhood.
There are a lot of reasons why oncologists aren't exactly brimming with excitement at the idea of getting their hands on Eli Lilly's lung cancer drug necitumumab.